Verteporfin, a YAP1 inhibitor, decreases Wnt5A expression and EMT markers, emphasizing the potential of targeting Wnt5A in ovarian cancer (Dehghani-Ghobadi et al., 2022[25]). Here, YAP1 is linked to ovarian carcinoma.